Kyoto University: Granted iPS cell license to Avery: Cardiomyocyte manufacturing method
Startup from Kyoto University: “Myoridge”
On April 19, a non-exclusive licensing agreement was signed with Avery Therapeutics (Avery) of the United States.
US Avery Therapeutics (Avery):
Avery Therapeutics (Avery) of the United States is a company that develops regenerative medicine-related products using iPS cell-derived cardiomyocytes.
Avery is developing advanced treatments for patients suffering from cardiovascular disease.
Major development pipeline
It is a regenerative medicine product MyCardia under development for the treatment of chronic heart failure.
iPS cell licensing
Avery will be licensed for a method for inducing differentiation of iPS cell-derived cardiomyocytes owned by Kyoto University and Myoridge.
This contract is
As a method for producing iPS cell-derived cardiomyocytes,
Provide clinical application technology to overseas,
This is the first license agreement.
Avery is manufactured and sold in North America
Of products using the differentiation induction method,
Manufacture, development and sales in North America
Get non-exclusive rights.
Currently, Avery’s products are in the stage of non-clinical trials.
Basic technology of Myoridge
In addition to the guidance method licensed from Kyoto University, we have the following basic technologies.
iPS cell stem cells and
Mesoderm-derived cells,
Cardiomyocytes,
Mesenchymal stem cells,
Blood cell lines, etc.
Myoridge has “basic technology for manufacturing”.
In the future, it is said that it will contribute to the spread of regenerative medicine by sending out highly original basic technology to the world.
https://jp.techcrunch.com/2021/04/19/myoridge-avery-therapeutics/
April 19, 2021
Myoridge. Co. Ltd.
Myoridge completes out-license agreement with United States-based regenerative medicine company Avery Therapeutics for iPS cell-derived cardiomyocytes
Myoridge Co. Ltd. (President: Naohiro Makita)
has signed a license agreement with Avery Therapeutics, Inc. (“Avery”), a company based in Arizona that develops regenerative medicine products using iPS cell-derived cardiomyocytes.
Myoridge provides to Avery
a non-exclusive license for the method of inducing differentiation of iPS cell-derived cardiomyocytes owned by Myoridge and licensed from Kyoto University.
Under this agreement,
Avery will use the differentiation induction method to generate cells that will be used in Avery’s products, which are currently in the pre-clinical research stage.
This Agreement gives Avery a non-exclusive right to manufacture,
develop and sell products using this differentiation induction method in North America.
This agreement
is the first published license agreement for the manufacture of iPS cell-derived cardiomyocytes technology owned by Kyoto University,
which aims to provide technology for clinical application to companies internationally.
Myoridge
has basic technology for producing stem cells such as iPS cells and mesoderm-derived cells (cardiomyocytes, mesenchymal stem cells, blood cell lines, etc.)
and has licensed the differentiation induction method from Kyoto University.
Myoridge
will continue to contribute to the spread of regenerative medicine by providing highly unique basic technologies to the world.
About Myoridge
A start-up company established based on the research results of Kyoto University, which induces differentiation of pluripotent cells into differentiated cells, including myocardial cells by suspension culture without expensive proteins by using low-molecular-weight compounds.
This differentiation induction method is licensed from Kyoto University.
In addition to selling iPS cell-derived cardiomyocytes utilizing the technology, we offer custom-made, medium development support and manufacturing process development
support using our own low-molecular-weight compound database and patent-pending medium component search technology.
http://myoridge.co.jp/wp/wp-content/uploads/20210301_News_Release_Myoridge_Licence_Agreement.pdf
Myoridge Co. Ltd.